AU2009324709B2 - Crystalline forms of a 3-carboxypropyl-aminotetralin compound - Google Patents

Crystalline forms of a 3-carboxypropyl-aminotetralin compound Download PDF

Info

Publication number
AU2009324709B2
AU2009324709B2 AU2009324709A AU2009324709A AU2009324709B2 AU 2009324709 B2 AU2009324709 B2 AU 2009324709B2 AU 2009324709 A AU2009324709 A AU 2009324709A AU 2009324709 A AU2009324709 A AU 2009324709A AU 2009324709 B2 AU2009324709 B2 AU 2009324709B2
Authority
AU
Australia
Prior art keywords
methoxy
crystalline solid
solid form
crystalline
diethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009324709A
Other languages
English (en)
Other versions
AU2009324709A1 (en
Inventor
Sean Dalziel
Miroslav Rapta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Theravance Biopharma R&D IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D IP LLC filed Critical Theravance Biopharma R&D IP LLC
Publication of AU2009324709A1 publication Critical patent/AU2009324709A1/en
Assigned to THERAVANCE BIOPHARMA R&D IP, LLC reassignment THERAVANCE BIOPHARMA R&D IP, LLC Request for Assignment Assignors: THERAVANCE, INC.
Application granted granted Critical
Publication of AU2009324709B2 publication Critical patent/AU2009324709B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009324709A 2008-12-10 2009-12-09 Crystalline forms of a 3-carboxypropyl-aminotetralin compound Ceased AU2009324709B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12125408P 2008-12-10 2008-12-10
US61/121,254 2008-12-10
PCT/US2009/067271 WO2010068649A1 (en) 2008-12-10 2009-12-09 Crystalline forms of a 3-carboxypropyl-aminotetralin compound

Publications (2)

Publication Number Publication Date
AU2009324709A1 AU2009324709A1 (en) 2011-06-30
AU2009324709B2 true AU2009324709B2 (en) 2015-07-16

Family

ID=42122774

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009324709A Ceased AU2009324709B2 (en) 2008-12-10 2009-12-09 Crystalline forms of a 3-carboxypropyl-aminotetralin compound

Country Status (21)

Country Link
US (4) US8101794B2 (enExample)
EP (1) EP2376427B1 (enExample)
JP (1) JP5650657B2 (enExample)
KR (1) KR101685187B1 (enExample)
CN (1) CN102245564B (enExample)
AR (1) AR074592A1 (enExample)
AU (1) AU2009324709B2 (enExample)
BR (1) BRPI0922920A2 (enExample)
CA (1) CA2745441C (enExample)
CL (1) CL2011001391A1 (enExample)
CO (1) CO6390054A2 (enExample)
ES (1) ES2645087T3 (enExample)
IL (1) IL213093A0 (enExample)
MX (1) MX2011006209A (enExample)
MY (1) MY179041A (enExample)
NZ (1) NZ593377A (enExample)
RU (1) RU2512390C2 (enExample)
SG (1) SG172016A1 (enExample)
TW (1) TWI449685B (enExample)
WO (1) WO2010068649A1 (enExample)
ZA (1) ZA201104319B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2231589B1 (en) 2007-12-11 2013-02-13 Theravance, Inc. Aminotetralin compounds as mu opioid receptor antagonists
CA2707981C (en) * 2007-12-11 2016-05-10 Theravance, Inc. 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
CN103814010A (zh) * 2011-09-30 2014-05-21 施万制药 3-[2-甲磺酰基-1-(4-三氟甲基苯氧基)乙基]吡咯烷化合物的结晶形式

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076408A2 (en) * 2007-12-11 2009-06-18 Theravance, Inc. 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498196B1 (en) 1998-12-22 2002-12-24 Edward Roberts Compounds useful in pain management
US6844368B1 (en) 1998-12-22 2005-01-18 Edward Roberts Compounds useful in pain management
US6231594B1 (en) 1999-08-11 2001-05-15 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
AU2003241453A1 (en) * 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
MXPA05010821A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
JP2010509227A (ja) 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル，コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与
EP1997493A1 (en) * 2007-05-28 2008-12-03 Laboratorios del Dr. Esteve S.A. Combination of a 5-HT7 receptor ligand and an opioid receptor ligand
EP2231589B1 (en) 2007-12-11 2013-02-13 Theravance, Inc. Aminotetralin compounds as mu opioid receptor antagonists
ES2431354T3 (es) 2008-04-01 2013-11-26 Theravance, Inc. Derivados de 2-aminotetralina como antagonistas del receptor de opioide mu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076408A2 (en) * 2007-12-11 2009-06-18 Theravance, Inc. 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRUNDT, P. et al, Journal of Medicinal Chemistry, 2004, vol. 47, pp. 5069-5075 *

Also Published As

Publication number Publication date
TW201026646A (en) 2010-07-16
CL2011001391A1 (es) 2011-11-11
AU2009324709A1 (en) 2011-06-30
JP2012511580A (ja) 2012-05-24
ES2645087T3 (es) 2017-12-04
SG172016A1 (en) 2011-07-28
KR101685187B1 (ko) 2016-12-09
CO6390054A2 (es) 2012-02-29
US20100144881A1 (en) 2010-06-10
CN102245564B (zh) 2015-04-01
RU2011128393A (ru) 2013-01-20
CA2745441C (en) 2017-10-17
US8486958B2 (en) 2013-07-16
EP2376427B1 (en) 2017-08-02
TWI449685B (zh) 2014-08-21
US20130065916A1 (en) 2013-03-14
US8324236B2 (en) 2012-12-04
NZ593377A (en) 2013-07-26
MX2011006209A (es) 2011-07-12
US8969367B2 (en) 2015-03-03
MY179041A (en) 2020-10-26
KR20110093938A (ko) 2011-08-18
AR074592A1 (es) 2011-01-26
EP2376427A1 (en) 2011-10-19
WO2010068649A1 (en) 2010-06-17
ZA201104319B (en) 2012-03-28
CN102245564A (zh) 2011-11-16
JP5650657B2 (ja) 2015-01-07
US20130345466A1 (en) 2013-12-26
RU2512390C2 (ru) 2014-04-10
IL213093A0 (en) 2011-07-31
CA2745441A1 (en) 2010-06-17
US20120088834A1 (en) 2012-04-12
BRPI0922920A2 (pt) 2019-09-24
US8101794B2 (en) 2012-01-24

Similar Documents

Publication Publication Date Title
US10426766B2 (en) Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
AU2008335210B2 (en) 3 -carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
EP2231589B1 (en) Aminotetralin compounds as mu opioid receptor antagonists
US8969367B2 (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
WO2009124022A1 (en) 2 -aminotetralin derivatives as mu opioid receptor antagonists
HK1139399B (en) Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: THERAVANCE BIOPHARMA R&D IP, LLC

Free format text: FORMER APPLICANT(S): THERAVANCE, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired